VERODEXCopy

• DRUGBANK - Bicalutamide
• indication:

  For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.

• pharmacology:

• mechanism:

  Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.

• toxicity:

• absorprion:

  Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.

• halflife:

  5.9 days

• roouteelimination:

• volumedistribution:

• clearance:

  * Apparent oral cl=0.32 L/h [Normal Males]